HER3 expression was... significantly associated with decreased disease-specific survival HER2 cellular signaling is affected by the expression of other type 1 growth factor receptor family members ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody ... advanced EGFR-mutated non-small cell lung cancer (NSCLC).

HER3 is a protein expressed across several types of solid tumors, including breast cancer, EGFR-mutant non-small cell lung cancer and pancreatic cancer, and often associated with poor clinical ...

In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from ... or unresectable non-small cell lung cancer (NSCLC). Along with the $800 ...

Bispecific antibodies, which bind simultaneously to two different antigens, can attack tumors via novel mechanisms of action that cannot be evoked with combinations of conventional monoclonal ...